Eli Lilly and Company

LLY

$769.79B

Mega Cap

NYSEPharmaceutical PreparationsPharmaceutical🇺🇸North AmericaINDIANAPOLIS47.0K employees

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Website

Drugs in Pipeline

328

Phase 3 Programs

177

Upcoming Catalysts

Next Catalyst

Feb 15, 2026

23d

Market Overview

Stock performance and market intelligence

Catalyst Timeline

35 upcoming, 1 past

Phase 2Next

LY3541860 Phase 2 Results Expected

February 2026~LY354186040

Primary completion for LY3541860 trial (NCT06859294) in Rheumatoid Arthritis

Source

Phase 2

LY3871801 Phase 2 Results Expected

February 2026~LY3871801

Primary completion for LY3871801 trial (NCT05848258) in Rheumatoid Arthritis

Source

⭐Phase 3

Orforglipron Phase 3 Results Expected

March 2026~Orforglipron2,749

Primary completion for Orforglipron trial (NCT05803421) in Type 2 Diabetes

Source

⭐Phase 3

Insulin Glargine Phase 3 Results Expected

March 2026~Insulin Glargine2,749

Primary completion for Insulin Glargine trial (NCT05803421) in Type 2 Diabetes

Source

Phase 2

LY3549492 Phase 2 Results Expected

April 2026~LY3549492275

Primary completion for LY3549492 trial (NCT06683508) in Obesity

Source

⭐Phase 3

Baricitinib Phase 3 Results Expected

April 2026~Baricitinib58

Primary completion for Baricitinib trial (NCT04088396) in Systemic Juvenile Idiopathic Arthritis

Source

Phase 2

Bimagrumab Phase 2 Results Expected

April 2026~Bimagrumab240

Primary completion for Bimagrumab trial (NCT06643728) in Obesity

Source

⭐Phase 3

Retatrutide Phase 3 Results Expected

April 2026~Retatrutide2,300

Primary completion for Retatrutide trial (NCT05882045) in Obesity

Source

⭐Phase 3

Mirikizumab IV Phase 3 Results Expected

May 2026~Mirikizumab IV60

Primary completion for Mirikizumab IV trial (NCT05784246) in Ulcerative Colitis

Source

⭐Phase 3

Tirzepatide Phase 3 Results Expected

May 2026~Tirzepatide150

Primary completion for Tirzepatide trial (NCT06047548) in Overweight

Source

Phase 2

Mevidalen Phase 2 Results Expected

May 2026~Mevidalen300

Primary completion for Mevidalen trial (NCT06538116) in Alzheimer Disease

Source

⭐Phase 3

Retatrutide Phase 3 Results Expected

May 2026~Retatrutide

Primary completion for Retatrutide trial (NCT05929079) in Type 2 Diabetes

Source

Phase 2

LY3848575 Phase 2 Results Expected

June 2026~LY3848575450

Primary completion for LY3848575 trial (NCT06568042) in Neuropathic Pain

Source

Phase 2

LY3841136 Phase 2 Results Expected

June 2026~LY3841136350

Primary completion for LY3841136 trial (NCT06603571) in Obesity

Source

Phase 2

LY3305677 Phase 2 Results Expected

June 2026~LY3305677

Primary completion for LY3305677 trial (NCT06143956) in Obesity

Source

Phase 2

Tirzepatide Phase 2 Results Expected

June 2026~Tirzepatide350

Primary completion for Tirzepatide trial (NCT06143956) in Obesity

Source

⭐Phase 3

Lebrikizumab Phase 3 Results Expected

July 2026~Lebrikizumab

Primary completion for Lebrikizumab trial (NCT06921759) in Atopic Hand and Foot Dermatitis

Source

⭐Phase 3

Semaglutide Phase 3 Results Expected

August 2026~Semaglutide

Primary completion for Semaglutide trial (NCT06260722) in Diabetes Mellitus, Type 2

Source

⭐Phase 3

Retatrutide Phase 3 Results Expected

August 2026~Retatrutide

Primary completion for Retatrutide trial (NCT06260722) in Diabetes Mellitus, Type 2

Source

Phase 2

Mazdutide Phase 2 Results Expected

August 2026~Mazdutide300

Primary completion for Mazdutide trial (NCT06817356) in Alcohol Use Disorder

Source

⭐Phase 3

LY3650150 Phase 3 Results Expected

September 2026~LY3650150450

Primary completion for LY3650150 trial (NCT06339008) in Perennial Allergic Rhinitis (PAR)

Source

Phase 2

Tirzepatide Phase 2 Results Expected

September 2026~Tirzepatide140

Primary completion for Tirzepatide trial (NCT05536804) in Overweight

Source

⭐Phase 3

Retatrutide Phase 3 Results Expected

October 2026~Retatrutide320

Primary completion for Retatrutide trial (NCT06297603) in Type 2 Diabetes

Source

⭐Phase 3

Pembrolizumab Phase 3 Results Expected

October 2026~Pembrolizumab1,016

Primary completion for Pembrolizumab trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source

⭐Phase 3

Cisplatin Phase 3 Results Expected

October 2026~cisplatin1,016

Primary completion for Cisplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source

⭐Phase 3

Carboplatin Phase 3 Results Expected

October 2026~carboplatin1,016

Primary completion for Carboplatin trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source

⭐Phase 3

Pemetrexed Phase 3 Results Expected

October 2026~pemetrexed1,016

Primary completion for Pemetrexed trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source

⭐Phase 3

LY3537982 Phase 3 Results Expected

October 2026~LY35379821,016

Primary completion for LY3537982 trial (NCT06119581) in Carcinoma, Non-Small-Cell Lung

Source

Phase 2

MORF-057 Phase 2 Results Expected

November 2026~MORF-05739

Primary completion for MORF-057 trial (NCT06226883) in Inflammatory Bowel Diseases

Source

⭐Phase 3

Orforglipron Phase 3 Results Expected

November 2026~Orforglipron600

Primary completion for Orforglipron trial (NCT06649045) in OSA

Source

Phase 2

LY3938577 Phase 2 Results Expected

November 2026~LY3938577100

Primary completion for LY3938577 trial (NCT07215312) in Diabetes Mellitus, Type 2

Source

⭐Phase 3

Lasmiditan Phase 3 Results Expected

November 2026~Lasmiditan

Primary completion for Lasmiditan trial (NCT04396236) in Migraine

Source

Phase 2

Pirtobrutinib Phase 2 Results Expected

December 2026~Pirtobrutinib58

Primary completion for Pirtobrutinib trial (NCT06721013) in Immune Thrombocytopenia (ITP)

Source

Phase 2

LY3457263 Phase 2 Results Expected

December 2026~LY3457263240

Primary completion for LY3457263 trial (NCT06897475) in Type 2 Diabetes

Source

⭐Phase 3

Orforglipron Phase 3 Results Expected

January 2027~Orforglipron600

Primary completion for Orforglipron trial (NCT06972472) in Obesity

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Paclitaxel

Drug Name	Phase	Indication	Designations
Paclitaxel	Phase 3	Non Small Cell Lung Cancer	-
Ultra-Rapid Lispro	Phase 3	Type 1 Diabetes Mellitus	-
Insulin Lispro	Phase 3	Type 2 Diabetes Mellitus	-
Paclitaxel (Taxane)	Phase 3	Non-Small-Cell Lung Carcinoma	-
Human Insulin Inhalation Powder	Phase 3	Diabetes Mellitus, Type 2	-
dexamethasone	Phase 3	Non Small Cell Lung Cancer	-
Detemir	Phase 3	Diabetes Mellitus Type 2	-
docetaxel	Phase 3	Non-Small Cell Lung Cancer	-
tadalafil once a day [T(OaD)]	Phase 3	Erectile Dysfunction	-
Etanercept	Phase 3	Plaque Psoriasis	-
80 mg ixekizumab	Phase 3	Psoriasis	-
Insulin Degludec	Phase 3	Type 2 Diabetes Mellitus	-
Insulin lispro mix 25	Phase 3	Diabetes Mellitus Type 2	-
cDMARD	Phase 3	Rheumatoid Arthritis	-
LY2963016	Phase 3	Type 1 Diabetes	-
Ustekinumab	Phase 3	Plaque Psoriasis	-
olanzapine pamoate depot	Phase 3	Schizophrenia	-
LY2062430	Phase 3	Alzheimer's Disease	-
liposomal doxorubicin	Phase 3	Genital Neoplasms, Female	-
BEC2 Vaccine	Phase 3	Carcinoma, Small Cell Lung	-
Lebrikizumab	Phase 3	Atopic Dermatitis	-
LY3537982	Phase 3	Carcinoma, Non-Small-Cell Lung	-
amantadine	Phase 3	Schizophrenia	-
Insulin	Phase 3	Diabetes Mellitus, Type 2	-
venlafaxine	Phase 3	Anxiety Disorders	-
Necitumumab	Phase 3	Solid Tumors	-
enzastaurin	Phase 3	Non-Small Cell Lung Cancer	-
Retatrutide	Phase 3	Obesity	-
Capecitabine	Phase 3	Metastatic Gastric Adenocarcinoma	-
Tadalafil	Phase 3	Benign Prostatic Hyperplasia	-
Fulvestrant	Phase 3	Breast Neoplasms	-
Methylphenidate	Phase 3	Attention Deficit Hyperactivity Disorder	-
Glargine	Phase 3	Diabetes Mellitus, Type 1	-
lithium	Phase 3	Manic or Mixed Episode Associated With Bipolar I Disorder	-
Donanemab	Phase 3	Alzheimer Disease	-
Imlunestrant	Phase 3	Breast Neoplasms	-
Insulin Lispro Protamine Suspension	Phase 3	Diabetes Mellitus, Type 2	-
Somatropin	Phase 3	Growth Hormone Deficiency	-
Nasal Glucagon	Phase 3	Hypoglycemia	-
Lasmiditan	Phase 3	Migraine	-
Insulin Glargine	Phase 3	Diabetes Mellitus, Type 2	-
Olanzapine Hydrochloride	Phase 3	Bipolar Disorder	-
Oral antihyperglycemics	Phase 3	Diabetes Mellitus	-
Duloxetine hydrochloride	Phase 3	Diabetic Neuropathy, Painful	-
Tirzepatide Dose 1	Phase 3	Type2 Diabetes	-
Intramuscular Glucagon	Phase 3	Diabetes Mellitus, Type 1	-
Oral Antihyperglycemic Medications (OAMs)	Phase 3	Type 2 Diabetes Mellitus	-
oxaliplatin	Phase 3	Colorectal Cancer	-
Remternetug	Phase 3	Alzheimer's Disease	-
Fluoxetine	Phase 3	Major Depressive Disorder	-
Orforglipron	Phase 3	Obesity	-
Methylphenidate Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder	-
gemcitabine hydrochloride	Phase 3	Breast Cancer	-
Adalimumab	Phase 3	Rheumatoid Arthritis	-
Anastrozole	Phase 3	Breast Cancer	-
Insulin Lispro Protamine Suspension (ILPS)	Phase 3	Diabetes Mellitus, Type 2	-
Tadalafil 5 mg	Phase 3	Benign Prostatic Hyperplasia (BPH)	-
Human Insulin NPH	Phase 3	Diabetes Mellitus, Type 2	-
Drotrecogin alfa (activated)	Phase 3	Sepsis	-
Salmon Calcitonin	Phase 3	Osteoporosis	-
LY3537031	Phase 3	Alcohol Use Disorder	-
Abiraterone acetate	Phase 3	Prostate Cancer	-
Risedronate	Phase 3	Osteoporosis	-
LY4064809	Phase 3	Breast Neoplasms	-
Semaglutide	Phase 3	Type 2 Diabetes	-
Duloxetine 60 mg	Phase 3	Fibromyalgia	-
Topical corticosteroid	Phase 3	Atopic Dermatitis	-
Olomorasib	Phase 3	Carcinoma, Non-Small-Cell Lung	-
Intramuscular Olanzapine Depot	Phase 3	Schizophrenia	-
Insulin lispro 2 day reservoir in-use	Phase 3	Diabetes Mellitus, Type 1	-
Metformin	Phase 3	Type 2 Diabetes Mellitus	-
teriparatide 20 micrograms/day subcutaneous	Phase 3	Osteoporosis, Post-Menopausal	-
salmon calcitonin 100 IU/day subcutaneous	Phase 3	Osteoporosis, Post-Menopausal	-
Nasal Glucagon (NG)	Phase 3	Drug-specific Antibodies	-
Standard therapy for INCS	Phase 3	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	-
Lantus	Phase 3	Diabetes Mellitus, Type 2	-
Neutral protamine hagedorn insulin	Phase 3	Diabetes Mellitus, Type 2	-
Lasmiditan 100 mg	Phase 3	Acute Migraine	-
Gefitinib	Phase 3	Non Small Cell Lung Cancer	-
80 mg ixekizumab Dosing Regimen	Phase 3	Psoriasis	-
Ethinyl estradiol	Phase 3	Turner Syndrome	-
dirucotide	Phase 3	Secondary Progressive Multiple Sclerosis	-
Insulin Aspart	Phase 3	Type 2 Diabetes Mellitus	-
Ramucirumab DP (IMC-1121B)	Phase 3	Hepatocellular Carcinoma	-
Injectable insulin	Phase 3	Diabetes Mellitus, Type 2	-
5 mg Tadalafil	Phase 3	Benign Prostate Hyperplasia	-
Dapagliflozin	Phase 3	Type 2 Diabetes	-
SSRI	Phase 3	Major Depressive Disorder	-
leuprorelin	Phase 3	Idiopathic Short Stature (ISS)	-
Atomoxetine	Phase 3	Attention Deficit Hyperactivity Disorder	-
Doxorubicin	Phase 3	Breast Cancer	-
Somatropin (rDNA origin) for injection	Phase 3	Failure to Thrive	-
Rapid Acting Intramuscular Olanzapine	Phase 3	Schizophrenia	-
LY3650150	Phase 3	Perennial Allergic Rhinitis (PAR)	-
somatropin, rDNA origin, for injection	Phase 3	Growth Disorder	-
LY2189265	Phase 3	Diabetes Mellitus, Type 2	-
Sulfonylureas (SU)	Phase 3	Type 2 Diabetes Mellitus	-
50 mg etanercept	Phase 3	Psoriasis	-
LY2127399	Phase 3	Arthritis, Rheumatoid	-
Testosterone Solution	Phase 3	Hypogonadism	-
Pregabalin	Phase 3	Diabetic Neuropathy, Painful	-
Letrozole	Phase 3	Breast Cancer	-
Ixekizumab 80 mg Q4W	Phase 3	Psoriatic Arthritis	-
Arzoxifene	Phase 3	Osteoporosis, Postmenopausal	-
Mirikizumab	Phase 3	Ulcerative Colitis	-
Liraglutide	Phase 3	Type 2 Diabetes Mellitus	-
Etesevimab	Phase 3	COVID-19	-
Human regular U-500 insulin (CSII)	Phase 3	Type 2 Diabetes Mellitus	-
carboplatin	Phase 3	Breast Cancer	-
Ramucirumab	Phase 3	Gastric Adenocarcinoma	-
Rapid-Acting Intramuscular Olanzapine	Phase 3	Schizophrenia	-
Olanzapine and Fluoxetine combination (OFC)	Phase 3	Treatment Resistant Depression	-
Glimepiride	Phase 3	Diabetes Mellitus, Type 2	-
sildenafil	Phase 3	Impotence	-
Pegilodecakin	Phase 3	Pancreatic Cancer	-
Duloxetine (DLX)	Phase 3	Osteoarthritis Knee Pain	-
Paroxetine	Phase 3	Major Depressive Disorder	-
Galunisertib	Phase 3	Glioblastoma	-
prednisone	Phase 3	Prostate Cancer	-
Humalog Mix 50	Phase 3	Diabetes Mellitus, Type 1	-
Aducanumab	Phase 3	Mild Cognitive Impairment (MCI)	-
LY2216684 (edivoxetine)	Phase 3	Depressive Disorder, Major	-
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder	Phase 3	Diabetes Mellitus, Type 2	-
Oral Olanzapine	Phase 3	Schizophrenic Disorders	-
semagacestat	Phase 3	Alzheimer's Disease	-
Abiraterone	Phase 3	Prostatic Neoplasms	-
LY450139	Phase 3	Alzheimer's Disease	-
Vepugratinib	Phase 3	Carcinoma, Transitional Cell	-
Ruboxistaurin mesylate	Phase 3	Diabetic Neuropathies	-
Finasteride	Phase 3	Benign Prostatic Hyperplasia	-
Glucagon Nasal Powder	Phase 3	Diabetes Mellitus	-
Vinorelbine	Phase 3	Lung Neoplasms	-
cetuximab	Phase 3	Colorectal Neoplasms	-
80 mg Ixekizumab Dosing Regimens 1, 2, and 3	Phase 3	Psoriasis	-
etoposide	Phase 3	Non-small Cell Lung Cancer	-
insulin lispro injection [rDNA origin] Low Mix	Phase 3	Type 2 Diabetes Mellitus	-
Ramucirumab (IMC-1211B) DP	Phase 3	Gastric Cancer	-
Clopidogrel	Phase 3	Acute Coronary Syndrome	-
Prasugrel	Phase 3	Sickle Cell Anemia	-
Commercially-available Aspirin	Phase 3	Acute Coronary Syndrome	-
Eloralintide	Phase 3	Overweight	-
Selpercatinib	Phase 3	Non-Small Cell Lung Cancer	-
Pembrolizumab	Phase 3	Carcinoma, Non-Small-Cell Lung	-
ERA as specific PAH treatment	Phase 3	Hypertension, Pulmonary	-
tamoxifen	Phase 3	Metastatic Breast Cancer	-
Escitalopram	Phase 3	Major Depressive Disorder	-
Haloperidol	Phase 3	Schizophrenia	-
LANTUS®	Phase 3	Diabetes Mellitus, Type 2	-
Insulin Levemir	Phase 3	Diabetes Mellitus, Type 1	-
Bamlanivimab	Phase 3	COVID-19	-
Mirikizumab IV	Phase 3	Ulcerative Colitis	-
Olaratumab	Phase 3	Metastatic Pancreatic Cancer	-
Other standard therapy for ADHD	Phase 3	Attention Deficit Hyperactivity Disorder	-
Atomoxetine Hydrochloride	Phase 3	Attention Deficit Hyperactivity Disorder	-
Duloxetine	Phase 3	Urinary Stress Incontinence	-
LY2216684	Phase 3	Major Depressive Disorder	-
Insulin Efsitora Alfa	Phase 3	Type 2 Diabetes	-
Abemaciclib	Phase 3	Breast Cancer	-
LY3819253	Phase 3	COVID-19	-
LY900014	Phase 3	Type 1 Diabetes Mellitus	-
Gemcitabine	Phase 3	Non-Small Cell Lung Cancer	-
Ixekizumab Auto-Injector	Phase 3	Plaque Psoriasis	-
pemetrexed	Phase 3	Non-Small Cell Lung Cancer	-
Erlotinib	Phase 3	Non Small Cell Lung Cancer	-
GEMZAR	Phase 3	Pancreatic Neoplasms	-
Dulaglutide	Phase 3	Type 2 Diabetes Mellitus	-
LY2605541	Phase 3	Type 1 Diabetes Mellitus	-
Baricitinib	Phase 3	Systemic Juvenile Idiopathic Arthritis	-
cisplatin	Phase 3	Non-Small Cell Lung Cancer	-
Galcanezumab	Phase 3	Chronic Migraine	-
Ixekizumab	Phase 3	Psoriasis	-
Tirzepatide	Phase 3	Overweight	-
Remternetug (IV)	Phase 3	Alzheimer's Disease	-
LY353381	Phase 3	Breast Neoplasms	-
Insulin Peglispro	Phase 3	Type 2 Diabetes Mellitus	-
olanzapine	Phase 3	Bipolar Disorder I or II	-
teriparatide	Phase 3	Osteoporosis, Postmenopausal	-
Erbitux (Cetuximab)	Phase 2	Colorectal Neoplasms	-
Icrucumab	Phase 2	Colon Cancer	-
Mibavademab	Phase 2	Obesity	-
Hydrochlorothiazide	Phase 2	Mild Hypertension	-
LY3972406	Phase 2	Plaque Psoriasis	-
LY3372689	Phase 2	Alzheimer Disease	-
LY2140023	Phase 2	Schizophrenia	-
LY3209590	Phase 2	Type 2 Diabetes Mellitus	-
Tamsulosin	Phase 2	Benign Prostatic Hyperplasia	-
Pemetrexed - Phase 1	Phase 2	Ovarian Cancer	-
LY3041658	Phase 2	Hidradenitis Suppurativa	-
Folic Acid	Phase 2	Non Small Cell Lung Cancer	-
Loperamide	Phase 2	Breast Cancer	-
pegfilgrastim	Phase 2	Ovarian Cancer	-
5-Fluorouracil	Phase 2	Head and Neck Cancer	-
LY3841136	Phase 2	Obesity	-
IMC-1121B (ramucirumab)	Phase 2	Carcinoma, Non-Small-Cell Lung	-
Prophylactic Loperamide	Phase 2	Metastatic Breast Cancer	-
LY2189265 and Lifestyle Measures	Phase 2	Diabetes Mellitus, Type 2	-
Leucovorin	Phase 2	Stomach Cancer	-
LY2484595	Phase 2	Dyslipidemia	-
LY3039478	Phase 2	T-cell Acute Lymphoblastic Leukemia	-
DC-806	Phase 2	Plaque Psoriasis	-
LY3437943	Phase 2	Obesity	-
LY3016859	Phase 2	Osteoarthritis	-
LY2510924	Phase 2	Extensive Stage Small Cell Lung Carcinoma	-
MORF-057	Phase 2	Inflammatory Bowel Diseases	-
LY3549492	Phase 2	Obesity	-
LY293111	Phase 2	Pancreatic Cancer	-
LY2828360	Phase 2	Osteoarthritis, Knee	-
Testosterone MD-Lotion	Phase 2	Hypogonadism	-
Prexasertib	Phase 2	Ovarian Cancer	-
LY2409021	Phase 2	Diabetes Mellitus, Type 2	-
Granulocyte colony-stimulating factor (G-CSF)	Phase 2	Small Cell Lung Cancer	-
avastin	Phase 2	Colorectal Cancer	-
Eplerenone	Phase 2	Chronic Kidney Disease	-
LY3473329	Phase 2	Lipoprotein Disorder	-
LY517717	Phase 2	Total Knee Replacement	-
LY3857210	Phase 2	Diabetic Peripheral Neuropathic Pain	-
LY2951742	Phase 2	Migraine Headache	-
Enzyme-inducing antiepileptic drugs (EIAED)	Phase 2	Recurrent Glioblastoma	-
120 mg LY2784544	Phase 2	Neoplasms, Hematologic	-
Mitoxantrone	Phase 2	Prostate Cancer	-
Cixutumumab	Phase 2	Non-Small-Cell Lung Carcinoma	-
Prasugrel (CS-747)	Phase 2	Cardiovascular Diseases	-
sPLA2 Inhibitor	Phase 2	Sepsis	-
LY3526318	Phase 2	Chronic Low-back Pain	-
Standard of Care Single Agent Chemotherapy	Phase 2	Hormone Receptor Positive Breast Cancer	-
LY2495655	Phase 2	Pancreatic Cancer	-
LY3457263	Phase 2	Type 2 Diabetes	-
LY2189102	Phase 2	Arthritis, Rheumatoid	-
IMC-1121B	Phase 2	Cancer	-
LY3451838	Phase 2	Migraine	-
Platinol	Phase 2	Carcinoma, Transitional Cell	-
Brenipatide	Phase 2	Asthma	-
Nasal Glucagon 1 mg	Phase 2	Hypoglycemia	-
LY3202626	Phase 2	Alzheimer Disease	-
LY2623091	Phase 2	Primary Hypertension	-
LY3938577	Phase 2	Diabetes Mellitus, Type 2	-
Pemetrexed 500 mg/m2	Phase 2	Non-small Cell Lung Cancer	-
LY2428757	Phase 2	Diabetes Mellitus, Type 2	-
LOXO-292	Phase 2	Medullary Thyroid Cancer	-
olanzapine-RAIM	Phase 2	Schizophrenia	-
Tadalafil- Tablet or Oral suspension	Phase 2	Pulmonary Arterial Hypertension	-
LY3023414	Phase 2	Prostate Cancer Metastatic	-
Solbinsiran	Phase 2	Severe Hypertriglyceridemia	-
IMC-18F1	Phase 2	Breast Cancer	-
PPAR alpha	Phase 2	Hypercholesterolemia	-
5 - FU	Phase 2	Solid Tumor	-
LY2422347	Phase 2	Sleep Initiation and Maintenance Disorders	-
LY3561774	Phase 2	Dyslipidemias	-
LY3848575	Phase 2	Neuropathic Pain	-
Mevidalen	Phase 2	Alzheimer Disease	-
ALIMTA	Phase 2	Colorectal Cancer	-
Bimagrumab	Phase 2	Obesity	-
LY2603618	Phase 2	Non Small Cell Lung Cancer	-
Enzastaurin HCL	Phase 2	Non-Small-Cell Lung Carcinoma	-
LY2439821	Phase 2	Rheumatoid Arthritis	-
Dinutuximab	Phase 2	Relapsed Solid Tumor	-
LY451395	Phase 2	Alzheimer's Disease	-
IMC-A12	Phase 2	Prostate Cancer	-
Emibetuzumab	Phase 2	Carcinoma, Non-Small-Cell Lung	-
Testosterone Solution 2%	Phase 2	Ejaculatory Dysfunction	-
LY3016859 ISA	Phase 2	Osteoarthritis, Knee	-
Ramucirumab (IMC-1121B)	Phase 2	Breast Cancer	-
LY3154207	Phase 2	Lewy Body Dementia	-
LOXO-305	Phase 2	Leukemia, Lymphoid	-
Cetuximab + platinum + gemcitabine	Phase 2	Non-Small-Cell Lung Carcinoma	-
irinotecan	Phase 2	Metastatic Colorectal Cancer	-
arzoxifene hydrochloride	Phase 2	Endometrial Cancer	-
Methotrexate	Phase 2	Arthritis, Rheumatoid	-
Cyclophosphamide	Phase 2	Desmoplastic Small Round Cell Tumor	-
Ramucirumab DP	Phase 2	Carcinoma of Urinary Tract	-
Enzastaurin 500 milligram (mg) Once Daily (QD)	Phase 2	Glioblastoma Multiforme	-
Triamcinolone (Optional)	Phase 2	Atopic Dermatitis	-
naveglitazar	Phase 2	Diabetes Mellitus, Non-Insulin-Dependent	-
depot octreotide	Phase 2	Carcinoma	-
Mazdutide	Phase 2	Alcohol Use Disorder	-
LY545694 49 mg	Phase 2	Osteoarthritis Knee Pain	-
LY2181308 sodium	Phase 2	Prostate Cancer	-
LY3819469	Phase 2	Lipoprotein Disorder	-
LY686017	Phase 2	Social Phobia	-
LY573636-sodium	Phase 2	Ovarian Cancer	-
Zagotenemab	Phase 2	Alzheimer Disease (AD)	-
solanezumab	Phase 2	Alzheimer's Disease	-
Subcutaneous Teriparatide	Phase 2	Osteoporosis	-
STX-478	Phase 2	Breast Cancer	-
Folinic acid	Phase 2	Colorectal Carcinoma	-
LY3556050	Phase 2	Diabetic Peripheral Neuropathy	-
LY2452473	Phase 2	Erectile Dysfunction	-
Raloxifene	Phase 2	Vasomotor Symptoms	-
LY3305677	Phase 2	Obesity	-
Macupatide	Phase 2	Obesity	-
LY2875358	Phase 2	Carcinoma, Non-Small-Cell Lung	-
LY450139 dihydrate	Phase 2	Alzheimer's Disease	-
Dacarbazine	Phase 2	Metastatic Malignant Melanoma	-
LY3871801	Phase 2	Rheumatoid Arthritis	-
LY2157299	Phase 2	Hepatocellular Carcinoma	-
Merestinib	Phase 2	Biliary Tract Cancer	-
LY2196044	Phase 2	Alcohol Dependence	-
LY2181308	Phase 2	Non-small Cell Lung Cancer	-
tasisulam	Phase 2	Metastatic Melanoma	-
IMC-A12 (Cixutumumab)	Phase 2	Adenocarcinoma of the Prostate	-
LY2090314	Phase 2	Leukemia	-
Eltrekibart	Phase 2	Hidradenitis Suppurativa	-
Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)	Phase 2	Carcinoma, Non-Small-Cell Lung	-
human insulin inhalation powder (HIIP)	Phase 2	Diabetes Mellitus, Type 1	-
cetuximab (Erbitux ®)	Phase 2	Head and Neck Cancer	-
LY3502970	Phase 2	Obesity	-
Temozolomide	Phase 2	Sarcoma, Ewing	-
LY2541546	Phase 2	Osteoporosis	-
Bortezomib	Phase 2	Multiple Myeloma	-
S-1	Phase 2	Metastatic Gastric Adenocarcinoma	-
Atorvastatin	Phase 2	Dyslipidemias	-
LY2228820	Phase 2	Epithelial Ovarian Cancer	-
Sunitinib	Phase 2	Metastatic Renal Cell Carcinoma	-
Leucovorin (LV)	Phase 2	Colorectal Cancer	-
Pemetrexed Phase 1	Phase 2	Non-Small Cell Lung Cancer	-
LY3541860	Phase 2	Rheumatoid Arthritis	-
mitomycin C	Phase 2	Superficial Bladder Cancer	-
LY3462817	Phase 2	Rheumatoid Arthritis	-
LY3295668	Phase 2	Neoplasms	-
5 - Fluorouracil	Phase 2	Solid Tumor	-
Risperidone	Phase 2	Schizophrenia	-
LY3015014	Phase 2	Hypercholesterolemia	-
LY2523355	Phase 2	Metastatic Breast Cancer	-
LY2624803	Phase 2	Primary Insomnia	-
Pirtobrutinib	Phase 2	Lymphoma, Non-Hodgkin	-
Enoxaparin	Phase 2	Submassive Pulmonary Embolism	-
Sivelestat	Phase 2	Respiratory Distress Syndrome, Adult	-
IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg)	Phase 2	Hepatocellular Carcinoma	-

Eli Lilly and Company

Market Overview

LY3541860 Phase 2 Results Expected

LY3871801 Phase 2 Results Expected

Orforglipron Phase 3 Results Expected

Insulin Glargine Phase 3 Results Expected

LY3549492 Phase 2 Results Expected

Baricitinib Phase 3 Results Expected

Bimagrumab Phase 2 Results Expected

Retatrutide Phase 3 Results Expected

Mirikizumab IV Phase 3 Results Expected

Tirzepatide Phase 3 Results Expected

Mevidalen Phase 2 Results Expected

Retatrutide Phase 3 Results Expected

LY3848575 Phase 2 Results Expected

LY3841136 Phase 2 Results Expected

LY3305677 Phase 2 Results Expected

Tirzepatide Phase 2 Results Expected

Lebrikizumab Phase 3 Results Expected

Semaglutide Phase 3 Results Expected

Retatrutide Phase 3 Results Expected

Mazdutide Phase 2 Results Expected

LY3650150 Phase 3 Results Expected

Tirzepatide Phase 2 Results Expected

Retatrutide Phase 3 Results Expected

Pembrolizumab Phase 3 Results Expected

Cisplatin Phase 3 Results Expected

Carboplatin Phase 3 Results Expected

Pemetrexed Phase 3 Results Expected

LY3537982 Phase 3 Results Expected

MORF-057 Phase 2 Results Expected

Orforglipron Phase 3 Results Expected

LY3938577 Phase 2 Results Expected

Lasmiditan Phase 3 Results Expected

Pirtobrutinib Phase 2 Results Expected

LY3457263 Phase 2 Results Expected

Orforglipron Phase 3 Results Expected

AI Predictions & Institutional Flow

FDA Submissions

Drug Pipeline

Regulatory & News